Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GMA-106 by Gmax Biopharm for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
GMA-106 is under clinical development by Gmax Biopharm and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Data Insights
GMA-106 by Gmax Biopharm for Type 2 Diabetes: Likelihood of Approval
GMA-106 is under clinical development by Gmax Biopharm and currently in Phase I for Type 2 Diabetes. According to GlobalData,...